Orgovyx Offers New Oral Option for People With Prostate Cancer

With Chart: Over 75% of oncologists are likely to prescribe relugolix, and about one-half are likely to transition patients on leuprolide acetate to the agent

Feb 1, 2021

People being treated for advanced prostate cancer now have a new oral option, offering patients the ability to not have to visit a provider for administration — an especially welcome alternative during the COVID-19 pandemic. Industry experts point to an array of reasons as to why the new drug should expect to get a lot of use. And a recent Zitter Insights survey indicates that the majority of oncologist respondents likely will prescribe it, with many saying they expect to favor it over the current standard of care.
To access this post, you must purchase a subscription plan. Click Here to purchase.

Already a member? Click Here to login.
FebruaryMember Content